1. Home
  2. GMM vs MAIA Comparison

GMM vs MAIA Comparison

Compare GMM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Mofy Metaverse Limited

GMM

Global Mofy Metaverse Limited

N/A

Current Price

$1.19

Market Cap

60.9M

Sector

N/A

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.56

Market Cap

49.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GMM
MAIA
Founded
2017
2018
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.9M
49.3M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
GMM
MAIA
Price
$1.19
$1.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
170.8K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.87
52 Week High
$4.75
$3.19

Technical Indicators

Market Signals
Indicator
GMM
MAIA
Relative Strength Index (RSI) 48.46 39.24
Support Level $1.13 $1.20
Resistance Level $1.62 $1.66
Average True Range (ATR) 0.07 0.17
MACD 0.00 -0.06
Stochastic Oscillator 70.83 16.20

Price Performance

Historical Comparison
GMM
MAIA

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: